# Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

> **NCT04029480** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 166 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ertugliflozin 5 mg
- **DRUG:** Ertugliflozin 15 mg
- **DRUG:** Placebo to ertugliflozin 15 mg
- **DRUG:** Placebo to ertugliflozin 5 mg
- **BIOLOGICAL:** Insulin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT04029480
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-08
- **Primary completion:** 2025-04-11
- **Final completion:** 2025-04-11
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04029480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04029480, "Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04029480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*